Behaivior

Market position

Behaivior is a private, early-stage digital health company in the behavioral health, remote patient monitoring and wearable technology space, active since 2017 and funded primarily through grants, accelerator programs and early-stage instruments. Third-party data providers classify it under healthcare and life sciences with verticals spanning mental health, health IoT, medical AI, telemedicine and medical devices, and list OpiAID, DynamiCare Health and Lief Therapeutics as comparable companies. Its recognition includes multiple top-10 IBM Watson AI XPRIZE milestone placements and a Carnegie Science Award.

Behaivior positions its differentiation around proprietary AI-enabled predictions of pre-crisis events, including return to use, generated from wearable biomarker data, with a stated ability to predict craving events up to four hours in advance and trigger automatic, personalized interventions at that moment. It pairs these predictions with detailed assessment summaries, digital interventions and user-controlled alerting of care providers and support networks. The team spans business, UI/UX design, addiction and mental health science, consumer and behavioral technology, software development, human-computer interaction, artificial intelligence and machine learning, and the company is woman-owned and emphasizes gender and racial diversity in leadership as a means of mitigating AI bias.

Technology

The Recovery™ platform combines a wearable biomarker-tracking device with mobile and dashboard software and pattern-recognition AI. Proprietary machine learning models generate predictions of upcoming pre-crisis events, including return to use, and produce detailed assessment summaries; when a craving event is predicted within four hours, automated just-in-time interventions such as medication reminders, tailored coaching and push notifications to care providers and support networks are triggered. The platform provides real-time access to users' biometric data, remote monitoring for providers, a real-time alerting system and provider dashboard metrics, and operates under HIPAA-compliant data security protocols with informed consent required for user data. A third-party profile lists a technology stack including Amazon Web Services, Wix, Snowplow, Sentry, HubSpot, Calendly, Amazon Advertising and Taboola.

Go-to-market

The company pursues a B2B SaaS route to market, marketing to care providers and rehab centers, telehealth providers, employers and benefits leaders, and health plans through demo requests and a solutions contact address, while individuals and support-network members can sign up for the Recovery™ app directly. It also builds visibility through competitions, awards, grant funding, accelerator programs, press coverage and partnerships, and collects experiences from care providers, people in recovery and loved ones via a public response form and mailing list.

Behaivior serves individuals pursuing or in recovery from substance use, addiction and mental health disorders, along with their families and support networks; care providers and rehabilitation centers; telehealth providers; employers and benefits leaders seeking workforce mental health and EAP support; and health plans focused on outcomes, cost reduction and health equity in their member populations.

Geography

Behaivior is headquartered in Pittsburgh, Pennsylvania, United States, where it was founded and continues to be based, with operations reported in North America. Its founder engages with Pennsylvania state policy discussions, and the company aims to distribute its technology regardless of user location.

History

Behaivior was founded in Pittsburgh, Pennsylvania in January 2017 by Ellie Gordon, following a hackathon win that granted the team entry into the IBM Watson AI XPRIZE competition. The company was established to address the opioid epidemic. Since founding, it has won multiple competitions and grants and entered several incubator and accelerator programs, including AlphaLab and the Ignite Healthcare program, and placed in the top 10 worldwide in the first, second and final milestone rounds of the IBM Watson AI XPRIZE. It has received funding from Innovation Works, the National Institutes of Health, the National Science Foundation and others. In 2023 the founder was invited to the signing of a Pennsylvania executive order establishing a governance framework for ethical AI use in Commonwealth agencies.

Risks & controversies

The company cites the cost and time burden of understanding and maintaining compliance with evolving privacy laws and HIPAA obligations, noting that such requirements can deter healthcare providers from adopting new technologies. It also points to policy limitations that hinder broader adoption of technology tools in behavioral health, gaps in insurance coverage for remote monitoring solutions, and the risk of bias in AI systems, which it says it mitigates through diversity in leadership and team composition. Regulatory scrutiny of AI in healthcare as a high-risk area is an additional stated constraint on growth.